Company intelligence / Profile preview

Xiamen Wantai Canghai Biotechnology Co., Ltd.

Xiamen, Fujian, Chinabioplanassociates.com ↗

Ownership: Private
Development stage: Commercial

Overview

Xiamen Wantai Canghai Biotechnology Co., Ltd. has at least one product approved for marketing that plays a significant role in preventing pneumonia among infants and children. The company operates as part of the broader Wantai group, which specializes in vaccines and diagnostics targeting infectious diseases. Specific clinical trial results or broader pipeline details are not provided.

Therapeutic areas: Infectious Diseases
Modalities: VaccinesRecombinant protein vaccines (inferred from context and parent company’s focus)
Industry: Biotech

Drug pipeline

2 assets

Xin Kening

Commercial

Indications: Cervical cancer prevention

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Xiamen Wantai Canghai Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiamen Wantai Canghai Biotechnology Co., Ltd..

Explore the full profile